Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Vitamin D receptor binding, chromatin states and association with multiple sclerosis.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
[The influence of locomotor treatment using robotic body-weight-supported treadmill training on rehabilitation outcome of patients suffering from neurological disorders].
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.

Pages